Human cytochrome P450 (CYP) 3A4 is the most abundant hepatic and intestinal phase I
enzyme that metabolizes approximately 50% marketed drugs. The crystal structure of bound …

OBJECTIVES: To review recent advances in the understanding of molecular mechanisms of
drug disposition and cellular mechanisms of action and targets of colchicine, and disease …

The accuracy of in vitro inhibition parameters in scaling to in vivo drug-drug interactions
(DDI) was examined for over 40 drugs using seven human P450-selective marker activities …

Several human immunodeficiency virus (HIV) protease inhibitors, including atazanavir,
indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir, were tested for their potential to …

Phenotyping for drug metabolizing enzymes and transporters is used to assess
quantitatively the effect of an intervention (eg, drug therapy, diet) or a condition (eg, genetic …

Food–drug interaction studies are critical to evaluate appropriate dosing, timing, and
formulation of new drug candidates. These interactions often reflect prandial-associated …

AIM: To predict the magnitude of metabolic drug–drug interaction (mDDI) between triazolam
and diltiazem and its primary metabolite N-desmethyldiltiazem (MA). METHODS: Relevant in …

The cytochrome P450 enzymes (P450s or CYPs) are a class of heme-containing
monooxygenases responsible for the oxidative metabolism of a wide range of endogenous …

Human cytochrome P450 (CYP) 3A subfamily members (mainly CYP3A4 and CYP3A5)
mediate the metabolism of approximately half all marketed drugs and thus play a critical role …

Current assessment of drug-drug interaction (DDI) prediction success is based on whether
predictions fall within a two-fold range of the observed data. This strategy results in a …